Success for a new Generation of Basic Therapeutics The Janus-Kinase -Inhibitor Baricitinib in rheumatoid Arthritis

被引：0
|
作者：
Keysser, G. [1 ]
机构：
[1] Univ Klinikum Halle, Klin Innere Med 2, Dept Innere Med, Ernst Grube Str 40, D-06097 Halle, Saale, Germany
来源：
ZEITSCHRIFT FUR RHEUMATOLOGIE | 2017年 / 76卷 / 05期
关键词：
D O I：
10.1007/s00393-017-0307-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：461 / 462
页数：2
相关论文
共 50 条
  • [21] Janus kinase inhibitors for rheumatoid arthritis
    Yamaoka, Kunihiro
    CURRENT OPINION IN CHEMICAL BIOLOGY, 2016, 32 : 29 - 33
  • [22] Direct Effects of the Janus Kinase Inhibitor Baricitinib on Sensory Neurons
    Vazquez, Enrique
    Richter, Frank
    Natura, Gabriel
    Koenig, Christian
    Eitner, Annett
    Schaible, Hans-Georg
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (22)
  • [23] Treatment of Mucous Membrane Pemphigoid With Janus Kinase Inhibitor Baricitinib
    Sarny, Stephanie
    Hucke, Miriam
    El-Shabrawi, Yosuf
    JAMA OPHTHALMOLOGY, 2018, 136 (12) : 1420 - 1422
  • [24] BARICITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Taylor, P.
    Genovese, M. C.
    Keystone, E.
    Schlichting, D.
    Beattie, S.
    Macias, W.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 65 - 66
  • [25] Baricitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in an open-label, long-term extension study
    Taylor, P.
    Genovese, M.
    Keystone, E.
    Schlichting, D.
    Beattie, S.
    Macias, W.
    Lundmark, J.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2014, 43 : 59 - 59
  • [26] BARICITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN AN OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Taylor, Peter
    Genovese, Mark
    Keystone, Ed
    Schlichting, Douglas
    Beattie, Scott
    Macias, William
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : A31 - A31
  • [27] The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis
    Hodge, J. A.
    Kawabata, T. T.
    Krishnaswami, S.
    Clark, J. D.
    Telliez, J. -B.
    Dowty, M. E.
    Menon, S.
    Lamba, M.
    Zwillich, S.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (02) : 318 - 328
  • [28] A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
    Taylor, Peter C. C.
    Laedermann, Cedric
    Alten, Rieke
    Feist, Eugen
    Choy, Ernest
    Haladyj, Ewa
    de la Torre, Inmaculada
    Richette, Pascal
    Finckh, Axel
    Tanaka, Yoshiya
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (13)
  • [29] Sigmoid Diverticulitis - unusual visceral medical Side Effect of Treatment with the anti-inflammatory Janus Kinase Inhibitor Baricitinib (OlumiantTM) for Patients with Rheumatoid Arthritis
    Al-Madhi, Sara
    Hinnerichs, Mattes
    Croner, Roland S.
    Meyer, Frank
    INTERNIST, 2022, 63 (SUPPL 3): : 324 - 325
  • [30] Remission of anti-tumor necrosis factor-α antibody-induced palmoplantar pustulosis with the Janus kinase inhibitor baricitinib in a patient with rheumatoid arthritis
    Imafuku, Shinichi
    Maeyama, Akira
    JOURNAL OF DERMATOLOGY, 2021, 48 (05): : E240 - E241
12345